Last reviewed · How we verify
liposomal NDDP
At a glance
| Generic name | liposomal NDDP |
|---|---|
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma (PHASE2)
- Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma (PHASE1)
- Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies (PHASE1, PHASE2)
- Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies (PHASE1, PHASE2)
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies (PHASE2)
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- liposomal NDDP CI brief — competitive landscape report
- liposomal NDDP updates RSS · CI watch RSS
- NYU Langone Health portfolio CI